ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Systematic Review

Metastasis to the stomach: a systematic review

[version 1; peer review: 2 approved]
PUBLISHED 18 Oct 2023
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Background: This study reviews the literature on gastric metastases (GM) in terms of diagnosis, treatment, and outcomes. The goal of this study was to provide clinicians with a reliable and beneficial source to understand gastric metastases arising from various primary tumors and to present the growing literature in an easily accessible form.
Methods: Articles published in English language from implementation of MEDLINE and Cochrane databases until May 2022 were considered for the systematic review. Articles other than English language, letters to the editor, posters, and clinical images were excluded. Hematogenous and lymphogenic metastases were included whereas direct tumoral invasion and seeding were excluded. Articles and abstracts were analyzed and last selection was done after cross-referencing and by use of defined eligibility criteria.
Results: In total 1,521 publications were identified and 170 articles were finally included totaling 186 patients with GM. The median age of patients was 62 years. Gynecologic cancer was the most common cancer type causing GM (67 patients), followed by lung cancer (33 patients), renal cancer (20 patients), and melanoma (19 patients). One of the main treatment methods performed for metastasis was resection surgery (n=62), sometimes combined with chemotherapy (ChT) or immunotherapy. ChT was the other most used treatment method (n=78). Also, immunotherapy was amongst the most preferred treatment options after surgery and ChT (n=10).
Conclusions: As 172 case reports were screened in the systematic review from different journals, heterogeneity was inevitable. Some articles missed important information such as complete follow-up or clinical information. Moreover, since all of the included articles were case reports quality assessment could not be performed. Among 172 case reports reviewed, resection surgery was performed the most and was sometimes combined with ChT and immunotherapy. Further research about what type of treatment has the best outcomes for patients with gastric metastases is needed.

Keywords

Metastasis to stomach, gastric metastases, gastric metastasis, gastric cancer, stomach cancer

Introduction

Metastases to the stomach are rare conditions with poor prognosis that may present with both gastrointestinal and systemic symptoms, such as loss of appetite, abdominal pain, fatigue, nausea, and vomiting, with a reported incidence of 0.2-0.7% based on clinical and autopsy findings.1 Gastrectomy is thought to be the only potentially curative treatment for metastatic gastric cancer but the primary site of the tumor is also considered along with the type and grade of the tumor when planning treatment in gastric metastases. Therefore, chemotherapy is also an option for patients with higher grades and multi-focal cancers. This study reviews the literature on gastric metastases in terms of diagnosis, treatment, and outcomes. The intended goal of this study was to provide clinicians with a reliable and beneficial source to understand gastric metastases arising from various primary tumors and to present the growing literature in an easily accessible form by reviewing the case reports of different primary tumors separately with consideration of diagnosis, treatment, and clinical presentation which may vary from patient to patient depending on primary site of the tumor.

Methods

This systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.172 A computerized literature search through MEDLINE/PubMed and Cochrane databases was conducted until May 2022.

The following combination of keywords was used for the search: ({({gastric (MeSH Terms)} AND {neoplasm metastasis (MeSH Terms)}) OR (gastric metastasis)} OR {gastric metastases}) OR (metastasis to the stomach). The search was limited by filtering for “free full text” and “case reports.” After the decision of inclusion and exclusion criteria by the team, two of the reviewers independently screened and retrieved each report.

Hematogenous and lymphogenic metastases were included whereas direct tumoral invasion and seeding were excluded from the study. Articles other than the English language, letters to the editor, posters, and clinical images were excluded. After the studies were screened and separated based on the inclusion and exclusion criteria, reviewers were divided to groups based on primary tumor location. Each group contained two reviewers to collect the data from studies of its specific location for example metastasis from gynecologic cancers or lung cancers.

The following data were extracted from the databases: first author, number of cases, age, sex, site of the primary tumor, histology and treatment of primary tumor, treatment of metastasis, clinical presentation of gastric metastases (GM), synchronous or metachronous GM, the time between primary and secondary GM, diagnostic procedures, other metastasis, and overall survival.

Since the study only contains screening of case reports, assessment of bias risk was not performed and thus it is mentioned as a limitation of study in discussion section.

Results

The PRISMA flow chart below illustrates details about data collection (Figure 1).

61a63717-767c-43b7-ba27-99947bbe070a_figure1.gif

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart.

In total, 1,521 publications were identified and 170 articles were finally included totaling 186 patients with GM (101 female and 85 male). The median age of patients was 62 years (IQR: 55-70.5). Gynecologic cancer (including breast cancer) was the most common cancer type causing GM (66 patients), followed by lung cancer (33 patients), renal cancer (20 patients), and melanoma (19 patients) (Figure 2). Results are presented below according to the origin of the primary tumor. The main treatment method performed for metastasis was resection surgery (n=62, total, subtotal or partial gastrectomy, proximal gastrectomy, radical total gastrectomy with Roux-en-Y, wedge gastrectomy, and laparoscopic resection of gastric metastasis), sometimes combined with chemotherapy (ChT) or immunotherapy. Chemotherapy was the other most used treatment method (n=78). Also, immunotherapy was among the most preferred treatment options after surgery and chemotherapy (n=10).

61a63717-767c-43b7-ba27-99947bbe070a_figure2.gif

Figure 2. Pie chart demonstrating percentages of primary tumor sites of patients with metastasis to stomach.

Gynecologic cancer

The median age of the 66 patients was 57 years. In total, 46 cases had metastases other than GM. Bone was the most common site of metastasis. Five cases had no other metastases. The total number of cases in the breast group was 54, and one of them was a male patient. The median age of the breast group is 56, the youngest patient was 36 years old and the oldest patient was 84 years old. Invasive lobular carcinoma (ILC) had the largest number of patients in comparison to ovarian and uterine groups. A total of 31 patients presented with ILC. The ovarian group had nine patients; the median age was 61 years. The oldest patient was 73 years old; the youngest patient was 47 years old. The uterine group had two patients with ages 49 and 80 years. In most cases, systemic therapy was more effective than surgery. Surgical treatment had a role in palliative treatment. As a systemic treatment, chemotherapy was the most utilized treatment. Overall survival was given in only 25 cases and ranged from a few days to nine years. Six of the total patients are still alive. Table 1256 summarizes the findings of included studies regarding gynecologic cancers.

Table 1. Illustrating the data regarding metastasis from gynecologic cancers.

First authorNo of casesAgeSexSite of primary tumorHistology type of primaryTreatment of primaryTreatment of metastasisClinical presentation of GM
Fousekis et al.2164FBreastLobular CaChTChTDysphagia, dyspepsia
Watanabe et al.3171FBreastDuctal CaMastectomy and axillary lymph adenectomy, ChTEndocrine therapyAsymptomatic
Husain et al.4147FLeft breastDuctal CaNeoadjuvant ChT, mastectomy with a left axillary lymph adenectomy, adjuvant endocrine therapyN/SDyspepsia, weight loss, vomiting
Zhang et al.5146FBilateral breastLobular CaN/AN/AEpigastric discomfort
Jabi et al.6160FRight breastLobular CaPalliative ChTPalliative ChTEpigastralgia, gastric bleeding, Anemia
Johnson et al.7150FBreastDuctal CaLumpectomy, adjuvant RT, ChTN/SN/S
Okamoto et al.8151FBreastDuctal CaChTChTMelena, presyncope
Nehmeh et al.9158FRight breastDuctal CaRight modified mastectomy, left prophylactic mastectomy, adjuvant ChTN/SPerforated ulcer
Hanafiah et al.10171FLeft breastLobular CaLeft mastectomy, axillary clearance, ChT, RTChHoarseness, weight loss, early satiety
Teixeira et al.11140FRight breastLobular CaNeoadjuvant ChT, RT, conservative surgery for right breast and right axillary lymph nodeTotal gastrectomyNausea, epigastric discomfort, early satiety, weight loss
Kutasovic et al.12152FLeft breastInvasive Ca of no special typeLocal excision, adjuvant RT, ChT, hormone therapySubtotal gastrectomyN/S
Abdallah et al.13153FBreastLobular CaChT, hormone therapyN/SAbdominal pain, diffuse tenderness, abdominal distention
Liu et al.14182FLeft breastPhyllodes tumorsTotal mastectomy for recurrent tumor local excision, RTExcision surgery, RTAnemia, melena
Tang et al.15167FLeft breastDuctal CaLeft breast-conserving surgery, axillary lymphadenectomy, adjuvant ChT, RTN/SStomach pain
De Gruttola et al.16161FBreastLobular CaMastectomy, adjuvant ChT, RTTotal gastrectomy due to gastric perforationGastric perforation
Mohy-Ud-Din et al.17183FBreastLobular CaMastectomy, sentinel lymph nodes excision, adj. ChTN/ANausea, vomiting
Güler et al.18142FBreastDuctal CaN/ATotal gastrectomy due to gastric perforation, ChTAcute Abdomen
Cui et al.19142FEndometriumEndometrial AcaTotal hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomyNeoadjuvant ChT, partial gastrectomyN/S
Asmar et al.20184FBreastLobular CaLeft mastectomy, adjuvant ChT, RT, hormone therapyHormone therapyDyspepsia
Klair et al.21160FOvaryOvarian granulosa cell tumorTotal hysterectomy, bilateral salpingo-oophorectomyN/AReflux, abdominal pain, nausea, anorexia
Yang22147FOvaryOvarian serous cystadenocarcinomaTotal hysterectomy, bilateral salpingo-oophorectomy, pelvic and paraaortic lymphadenectomy, total omentectomyLaparoscopic resection, adjuvant ChTAbdominal pain
Bushan et al.23168FLeft breastLobular CaWide excision of breast lesion, ChT, RT, hormone therapyDistal gastrectomy with D2 lymphadenectomy, left axillary excision, ChTWeight loss, dysphagia
Zhang et al.24245FBreastLobular AcaLumpectomy, RT, ChTN/SN/S
64FBreastLobular AcaN/AN/AWeight loss
Jin et al.25155FBreastLobular CaNeoadjuvant ChT, radical mastectomy, ChT, RTChTN/S
Buka et al.26158FBreastInvasive lobular CaChT, hormone therapy, RTNeoadjuvant ChRT, total gastrectomy, adjuvant ChTAbdominal pain, weight loss
Dória et al.27166FBreastInvasive lobular CaLetrozoleTotal gastrectomy, lymphadenectomy, esophagojejunostomy with a Roux loop techniqueEpigastric pain, vomiting, weight loss
Hwangbo et al.28173FOvarySerous AcaCytoreductive surgery, adjuvant ChTDistal gastrectomy with Billroth I anastomosis, lymphadenectomyEpigastric pain, dyspepsia
Shetty et al.29256FBreastInvasive ductal CaBreast conservation therapy, adjuvant ChTChTEpigastric discomfort, non-bilious vomiting
61FBreastInvasive ductal CaLeft breast modified radical mastectomy, adjuvant RTPalliative ChTAbdominal pain, melena, abdominal distension
Geredeli et al.30147FBreastInvasive lobular CaPalliative ChTSubtotal stomach resection, ChTAsymptomatic
Kim et al.31158FOvarySerous AcaTotal hysterectomy with salpingo-oophorectomy, lymphadenectomy with total omentectomy, adjuvant ChTSubtotal gastrectomy, lymphadenectomy, ChTAsymptomatic
Fernandes et al.32151FBreastInvasive lobular CaQuadrantectomy, adjuvant ChT, adjuvant RT, hormone therapyTotal gastrectomy, adjuvant ChT, hormone therapyDyspepsia
Moldovan et al.33149FCervix uteriSCCSurgery, ChRTSubtotal gastrectomy, lymphadenectomy D2, anastomotic layout shaped as Y Roux, omentectomy, adjuvant ChRTPyloric stenosis, epigastric pains, late postprandial emesis, weight loss
Zhou and Miao34161FOvarySerous AcaOptimal debulking cytoreductive surgery, adjuvant ChTGastric antrectomyAsymptomatic
Critchley et al.35162FBreastInvasive lobular CaMastectomy, level 2 axillary clearance, adjuvant ChT, adjuvant RT, adjuvant hormone therapyChTLoose stool, normocytic anemia, weight loss
Hara et al.36174FBreastInvasive ductal CaBreast-conserving surgeryPaclitaxelChronic gastritis
Ciulla et al.37170FBreastLobular CaPostoperative hormone therapyTotal gastrectomy, lymphadenectomy R1, esophagojejunostomy with Roux loose techniqueAsymptomatic
Jones et al.38251FBreastLobular CaWide local excision, axillary dissection, adjuvant RTTotal gastrectomy with Roux-en-Y reconstruction, hormone therapyWeight loss, epigastric pain
61FBreastLobular CaMastectomy, axillary dissection, adjuvant ChT, RT, tamoxifenChT, RTProgressive dysphagia, weight loss
Yim et al.39148FBreastSRCCChTChTEpigastric discomfort
Wong et al.40172FBreastInvasive lobular CaWide local excision, adjuvant RTHormone therapyAcute abdomen, rebound tenderness, generalized peritonitis
Ricciuti et al.41165MBreastInvasive ductal CaTotal mastectomy, complete axillary dissection, adjuvant hormone therapyGastrectomy with Roux-en-Y esophagojejunostomy anastomosisHematemesis, epigastric pain
Fernandes et al.42456 (the mean age)FBreastInvasive lobular CaChT, hormone therapyTotal gastrectomyUlcerated lesion, major bleeding
56 (the mean age)FBreastInvasive lobular CaChT, RT, hormone therapyChRTDiffuse infiltration
56 (the mean age)FBreastInvasive ductal CaChT, hormone therapyChTInfiltrative, ulcerated, stenotic lesion
56 (the mean age)FBreastInvasive ductal CaChT, hormone therapyChRTFlat erosive lesion
Zullo et al.43349FOvarySerous AcaHysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy, adjuvant ChTChTAbdominal pain, vomiting, weight loss
80FCervix uteriLeiomyosarcomaTotal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy, adjuvant ChTN/AEpigastric pain
70FBreastN/ARadical left mastectomy, adjuvant ChTChTDysphagia, epigastric pain
Villa Guzman et al.44158FBreastInvasive lobular CaQuadrantectomy, lymphadenectomy, adjuvant ChT, RTChT, hormone therapyNausea, epigastric pain
Mizuguchi et al.45171FOvarySerous AcaTotal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, ChTChT, hormone therapyAsymptomatic
Jmour et al.46451FBreastMixedRadical mastectomy with lymphadenectomyChT, RTNausea, vomiting, abdominal pain
47FBreastLobular infiltrating CaRadical mastectomy with lymphadenectomyChT, RTNausea, vomiting, abdominal pain
51FBreastDuctal infiltrating CaN/AChT, RTNausea, vomiting, abdominal pain
36FBreastLobular infiltrating CaRadical mastectomy with lymphadenectomyChT, RTNausea, vomiting, abdominal pain
Yim47165FBreastInvasive lobular CaModified radical mastectomy, adjuvant ChT, adjuvant RTChTDyspepsia, anorexia, indigestion, epigastric discomfort, early satiety, weight loss
Choi et al.48144FBreastPhyllodes tumorRight lumpectomy, axillary lymphadenectomy, RT, right total mastectomyEndoscopic hemostasis with cauterizationDizziness, anemia, melena
Khan et al.49156FBreastSignet ring AcaChTChTAnemia
Mullally et al.50146FBreastInvasive ductal CaLeft mastectomy, adjuvant ChT, hormone therapy, RTPalliative laparoscopic gastroduodenostomy, hormone therapy, palliative ChTEpigastric and left shoulder pain, epigastric tenderness, upper abdominal rigidity
Kliiger and Gorbaty51160FBreastInvasive ductal AcaSystemic therapy, ChTN/ANausea, diarrhea, vomiting, weight loss
Antonini et al.52161FOvarySerous CaChT, cytoreductive surgeryChTDyspepsia
Kono et al.53164FOvaryMucinous CaBilateral salpingo-oophorectomy, simple hysterectomy, pelvic and para-aortic lymphadenectomy, partial omental resectionChTBack pain
Kim et al.54139FBreastInvasive lobular CaRight breast-conserving surgery, lymphadenectomyDuodenal stent, systemic ChTUpper abdominal discomfort and pain, indigestion
Woo et al.55151FBreastInvasive lobular CaBilateral modified radical mastectomy, ChT, RTRadical subtotal gastrectomy with Billroth II anastomosis, D2 lymphadenectomy, ChTEpigastric pain
Ulmer et al.56155FBreastInvasive lobular CaBilateral mastectomy, adjuvant ChT, RT, hormone therapyPalliative pyloric stentNausea, vomiting, early satiety, weight loss

Gastrointestinal cancer

Median age of the 16 patients (11 male, five female) was 69 years, ranging from 22 years to 85 years. Overall survival of the seven patients whose data were given ranged from two months to 16 months. Although, there were six cases who were still alive and the survival of three cases was not reported. Among histological types of gastrointestinal cancers, adenocarcinoma (Adeno Ca) was the most common cancer type (seven patients), followed by hepatocellular cancer (HCC) (four patients) and squamous cell carcinoma (two patients). Endoscopy is the most frequently used method in the diagnosis of metastases. Methods such as computer tomography (CT), positron emission tomography and computed tomography (PET-CT), and endoscopic ultrasound were also used for diagnosis. One patient underwent laparotomy and biopsy. According to this research nine of these patients had surgery. Transcatheter left gastric artery embolization was performed in one patient. On the other hand, seven patients received chemotherapy and one patient had palliative radiotherapy. Nevertheless, one patient is unknown. Findings regarding gastrointestinal cancers are summarized in Table 2.5772

Table 2. Illustrating data regarding metastasis from gastrointestinal cancers.

First authorNo of casesAgeSexSite of primary tumorHistology type of primaryTreatment of primaryTreatment of metastasisClinical presentation of GM
Iwai et al.57176FTransverse colonPoorly differentiated Aca with a partial component of signet-ring CaChTChTAnemia, anorexia
Yang et al.58174FHead of pancreasPoorly differentiated invasive AcaChTChTRUQ pain
Lee and Lee59182MRight colonModerately differentiated AcaExtended right hemicolectomy (declined adjuvant ChT)Radical total gastrectomy (declined adjuvant ChT) with Roux-en-Y and D2 dissectionAsymptomatic
Rothermel et al.60161MBody of pancreasWell-differentiated ductal AcaDistal pancreatectomy, splenectomy, adjuvant ChTChT, palliative radiation, and wedge gastrectomyAsymptomatic
Terashima et al.61161FTransverse colonPoorly differentiated AcaExtended right hemicolectomy, ChTPartial gastrectomy and D3 dissection, ChTDiarrhea, vomiting
Sasajima et al.62172MHead and tail of pancreasIPMNChTChT (terminated after 2 courses)N/A
Tomonari et al.63178MBody and distal pancreasModerately differentiated ACa T3N0M0Surgery, adjuvant ChTSubtotal gastrectomyFollow-up
Adachi64167FPancreasWell-differentiated SCCDistal pancreatectomy and splenectomyTotal gastrectomyAnorexia, back pain
Nakazawa et al.65159MEsophagusMucosal SCCSubtotal esophagectomy, left lateral segmentectomy of liver, pancreatosplenectomy, adjuvant ChTProximal gastrectomyAsymptomatic
Abouzied et al.66169MLiverHCCRight hepatectomyChTIron-deficiency anemia
Ito et al.67178MLiverICCLateral hepatectomyProximal gastrectomy and lymphadenectomyFatigue
Imai et al.68162MLiverHCCN/ATranscatheter left gastric artery embolizationAbdominal mass
Kim et al.69175MLiverHCCRight hemihepatectomy, TACEGastric wedge resectionMelena, mild dyspnea
Peng et al.70122MLiverHCCRight hemihepatectomy combined with left lateral tumor local resection, cholecystectomy, splenectomyGastric tumor local resectionAnemia, FOBT 4+
Kanthan et al.71185MColonAcaN/AN/AAnemia
Wang et al.72163FGallbladderMelanomaSurgery, ChTChTPostprandial nausea, vomiting

Lung cancer

The median age of the 33 patients (25 male, eight female) was 62, ranging from 39 years to 78 years. Twenty- seven of the total cases had other metastases in addition to gastric ones. The survival time of the 22 patients whose data were given ranged from two weeks to 30 months. Yet, there were two cases that were still alive four and five years after metastases were found, respectively. Among histological types of primary lung cancers that lead to gastric metastases, adenocarcinoma was the most typical diagnosis (13 patients), followed by small cell lung cancer (SCLC) and squamous cell carcinoma (SCC). Regarding the treatment of GM, different combinations of chemotherapy were the most common choice (15 patients). On the other hand, seven of the total cases received surgical treatment (one esophagogastrostomy, two total, and four partial gastrectomies). However, since one patient’s metastasis was diagnosed after an autopsy, he could not receive any gastric treatment. Moreover, one patient refused any metastasis treatment, while six other cases’ treatments are unknown. Data pertaining to GM originating from primary lung cancers are summarized in Table 3.73102

Table 3. Illustrating data regarding metastasis from lung cancers.

First authorNo of casesAgeSexSite of primary tumorHistology type of primaryTreatment of primaryTreatment of metastasisClinical presentation of GM
Catalano et al.73178MLung - right upper lobePoorly differentiated AcaUpper right lobectomyTotal gastrectomyAsymptomatic
Shih-Chun et al.74155MLung - right upper lobeNSCLCConcurrent chemoradiotherapyPalliative total gastrectomy, ChTGastric bleeding, ulcerative mass
Das Majumdar et al.75172MLungPoorly differentiated AcaPalliative RTImmunotherapy, ChTIdentified with body CT after pathological fracture
Liu et al.76158MLungAcaMiddle right lobectomy, neoadjuvant therapy, ChTChT, partial gastrectomyN/S
Nemoto et al.77164MLung - right lower lobeSCCAdjuvant ChTEsophagogastrostomyEpigastric pain, progressive dysphagia
He et al.78161MLungSCLCLeft lower lobectomyCardia resectionProgressive dysphagia
Yang et al.79159MLung - left upper lobePoorly differentiated metastatic carcinomaChTAnti-PD1 immunotherapyRight upper limb pain, epigastric discomfort
Li et al.80161MLung - right lower lobeSCCChTChT, gastrectomyProgressive abdominal distention
Bhardwaj et al.81139FLungSCCChT, nivolumabRTDizziness, melena
Badipatla et al.82165MLungAcaChT, palliative careChT, palliative careBilateral flank pain, nausea, vomiting, change in bowel habit
Qasrawi et al.83169FLung - left upper lobeAcaRTHospice careMelena, hypotension
Kim et al.84170FLungPleomorphic carcinomaRight bronchial artery embolization, right upper lobectomy, adjuvant ChTPartial gastrectomy, immunotherapyAbdominal pain
Maeda et al.85160FLungSCLCChTN/ANausea, vomiting
Struyf et al.86168MLungAcaChTChTSevere epigastric pain
Altintas et al.87155MLungAcaChTChTEpigastric pain, hematemesis, melena
Casella et al.88163MLungSCLCSupportive careSupportive careFever, weight loss, epigastric pain, constipation
Ohashi et al.89162MLungLarge cell carcinomaRight upper lobectomyChTAbdominal pain
Aokage et al.90269MLung - right upper lobePleomorphic carcinomaRight upper lobectomy, parietal pleura resectionPartial gastrectomy, splenectomyFatigue, anemia
62MLung - left upper lobePleomorphic carcinomaLeft upper lobectomyDistal gastrectomy, splenectomyN/A
Katsenos and Archondakis91161MLung - left upper lobeAcaChTChTUpper GIS bleeding
Diem et al.92162FLung - right upper lobeAcaN/AChTEpigastric pain
Hu et al.93154MLungSCCRT, right middle lobectomyNone (patient refused)Dysphagia
Koh et al.94146MLungPleomorphic carcinomaAntibioticsN/AAbdominal pain, tenderness
Hung et al.95147MLungSCCRT, ChTChTWeight loss, dysphagia
Taira et al.96164MLungPleomorphic carcinoma, AcaLeft upper lobectomyChTAnemia
Gao et al.97166MLungSCLCChTChT, supportive careEpigastric pain
Kim et al.98168MLungPoorly differentiated AcaLeft lower lobectomy, posterior segmentectomy right upper lobe (2004), left upper lobe wedge resection (2007), palliative chemotherapyPalliative ChTEpigastric pain, dyspepsia
Chen et al.99159FLungSarcomatoid carcinomaSupportive treatmentSupportive treatmentAbdominal pain, anorexia, weight loss
Dong et al.100160FLungGlomus tumorN/AN/AHemoptysis, melena, abdominal distension
Kim et al.101266MLungSCLCN/AN/AEpigastric pain, epigastric tenderness, fatigue
68MLungSCLCN/AN/AHemoptysis, weight loss
Del Rosario et al.102177FLungAcaChTPalliative careN/A
Kanthan et al.71175MLungAcaN/AN/AEpigastric pain, RUQ pain

Malign melanoma

The median age of the 19 patients (seven female, 12 male) was 67, ranging from 28 years to 89 years. In 16 patients, other organ metastases were also discovered in addition to malign melanoma. Overall survival was not mentioned in 10 cases. Two of these cases deceased two and four days after hospital admission respectively, and one patient died after a year. Moreover, one of these patients was alive at five years, and another was alive at six months. Overall survival of three cases is three, 27, and four months, respectively. One of these patients refused treatment, and one of them did not receive treatment. However, immunotherapy was applied to six patients, surgery to five patients, radiotherapy to two patients, and only supportive treatment to three patients. In addition, the treatment of GM was not mentioned in three cases. Table 4 summarizes the findings of included studies regarding malign melanoma.103121

Table 4. Illustrating data regarding metastasis from malignant melanoma.

First authorNo of casesAgeSexSite of primary tumorHistology type of primaryTreatment of primaryTreatment of metastasisClinical presentation of GM
Zhu et al.103136MRight plantarNodularMohs microsurgeryN/AAnorexia, nausea, vomiting
Yoshimoto et al.104182FFourth left toeAcral lentiginousSurgeryPalliative RTMelena
Okamoto et al.105179MEsophagusPigmented submucosal tumor-like growth in the esophagusNivolumabNivolumabGross hematuria, weight loss, cough, exertional dyspnea
Cortellini et al.106181MN/AN/AN/AN/AWeakness, hyporexia, anemia
Groudan et al.107166FVulvaN/AN/APalliative RT, immunotherapyFatigue, exertional dyspnea, hematemesis, weight loss, nausea
Syed et al.108149FBackN/ASurgeryImmunotherapy, supportive care, SRSAnorexia, abdominal pain, fatigue, weight loss, nausea, vomiting
Genova et al.109180MScalpLentigoRTImmunotherapyHypochromic anemia
Wong et al.110181FFootAcral lentiginousAmputation, CTDenied the treatmentDyspnea, fatigue, anemia
Grander et al.111167MRight hypochondrium, back, scalpSuperficial spreadingSurgeryTotal gastrectomy, radiosurgeryMelena
Carcelain et al.112165FN/AN/ASurgerySurgeryN/S
Lestre et al.113167MLower backSuperficial spreadingExcision, adjuvant immunotherapyNoN/S
Rana et al.114172MN/AN/AN/AN/AWeight loss, anorexia
Rovere et al.115168MN/AN/AN/ASupportive careN/S
Eivazi-Ziaei et al.116156MRight heel-ALMN/ASurgerySupportive careEpigastric pain
El-Sourani et al.117143FRight breastN/ASurgerySleeve gastrectomy after atypical resection, complete locoregional lymphadenectomyMelena, anemia
Buissin et al.118163MAnorectalHyperplastic polypAbdominoperineal resectionSupportive careTenderness in the RUQ
Bankar et al.119141FN/AN/AN/ASurgeryN/S
Mohan et al.120128MN/AN/AN/ATemozolomideAbdominal pain, anorexia, weight loss
Farshad et al.121189MChest wallN/ALocal excisionNivolumabFatigue, rigors, fever

Urogenital cancers

The median age of 20 patients (11 male and nine female) with kidney cancer was 68.5 years old. A total of 11 patients had metastases other than GM. Overall survival was mentioned only in four cases and ranged from two months to one year. One of the 20 patients did not receive any therapy for GM, whereas 13 patients underwent surgical treatment (four endoscopic mucosal resections, nine gastrectomies), four patients had chemotherapy and one patient was treated with radiotherapy. Regarding prostate cancer, the median age of the affected individuals was 67 years old. Concerning the GM treatment four patients received chemotherapy, one patient underwent mucosal resection, and one patient refused treatment. Overall survival was mentioned for three patients ranging from four months to 19 months. All four patients with testis cancer had other metastases and two of them received chemotherapy. One study included bladder cancer without other metastases and the patient was referred to palliative care. Data pertaining to gastric metastases originating from primary urogenital cancers are summarized in Table 5.71,122151

Table 5. Illustrating data regarding metastasis from urogenital cancers.

First authorNo of casesAgeSexSite of primary tumorHistology type of primaryTreatment of primaryTreatment of metastasisClinical presentation of GM
Tapasak and Mcguirt122177MKidneyRCCNephrectomy, ChTRoux-en-Y gastric bypassGastrointestinal bleeding, anemia
Podzolkov et al.123130MTestisChoriocarcinomaChTN/AEpigastric pain, dyspnea
Koterazawa et al.124170FKidneyRCCNephrectomyEndoscopic submucosal resectionWeight loss
Hakim et al.125186FKidneyRCCNephrectomy, ChTRTGastrointestinal bleeding
Yoshida et al.126185FKidneyRCCNephrectomyEndoscopic resectionAnemia, melena
Bernshteyn et al.127168MKidneyRCCNephrectomyN/ADyspnea, melena
Weissman et al.128270MKidneyRCCNephrectomyChTDyspepsia, malaise, weight loss
85MKidneyRCCNephrectomyChTDyspepsia, malaise, weight loss
Chaar et al.129130MTestisChoriocarcinomaOrchiectomyChT (patient refused)Melena, anemia
Arakawa et al.130180FKidneyRCCChtChTAnorexia, pyrexia, malaise
Uehara et al.131173MKidneyRCCNephrectomy, ChTEndoscopic mucosal resection, immunotherapyGastric mass
O'Reilly et al.132159FKidneyClear cell RCCNephrectomyLaparoscopic sleeve gastrectomyAsymptomatic
Abu Ghanimeh et al.133167MKidneyClear cell RCCNephrectomyNo treatment initiatedGastrointestinal bleeding
Mazumdar et al.134149MTestisSeminomaN/AN/AAbdominal pain
Barras et al.135153MKidneyRCCNephrectomyPartial gastrectomyHematochezia
Riviello et al.136168MKidneyRCCNephrectomyGastrectomy, ChTMelena, postural dizziness, weakness
Hong et al.137160MBladderClear cell urothelial CaChT, RTPalliative careProjectile vomiting
Onitilo et al.138257MProstateAcaLHRH agonistChTWeakness, nausea, vomiting, hematemesis
89MProstateAcaLHRH agonistChTWeakness, nausea, vomiting, hematemesis
Tiwari et al.139158FKidneyClear cell RCCN/ARoux-en-Y subtotal gastrectomyMelena, hematemesis, fatigue
Yodonawa et al.140173MKidneyLeiomyosarcomaNephrectomyDistal gastrectomyMelena, weakness
Chibbar et al.141169FKidneyClear cell RCCNephrectomyEndoscopic mucosal resectionFatigue, lightheadedness, anemia
Sakurai et al.142161MKidneyRCCNephrectomyPartial gastrectomy, ChTMelena, anemia
Patel et al.143171MProstateAcaSurgery, RTN/AWeakness, dizziness, anemia
Sharifi et al.144117FKidneyPrimitive neuroectodermalChTChTAbdominal pain, distention
Greenwald et al.145162MKidneyClear cell RCCNephrectomyPartial gastrectomyTesticular pain
Costa et al.146166FKidneyRCCNephrectomyPalliative laparoscopic wedge resectionAnemia
Soe et al.147164MProstateN/ALHRH agonistPalliative care (patient refused chemotherapy)Anemia, melena
Bhandari and Pant148158MProstateAcaLHRH agonistChTAbdominal pain
Lowe et al.149118MTestisChoriocarcinomaChT, orchidectomyChTMelena, lethargy, dizziness
Inagaki et al.150175MProstateAcaLHRH agonistEndoscopic mucosal resection, hormone therapyEpigastric pain
Tavukcu et al.151167MProstateMixed 55% ductal 45% acinarProstatectomy, RTAndrogen deprivation therapy, ChTAscites, vomit
Kanthan et al.71119MTestisPredominantly choriocarcinoma, embryonal CaOrchiectomyPartial gastrectomy聽Melena, anemia

Others

The median age of the four patients with Merkel cell carcinoma was 73 years old. Two patients had other metastases in addition to GM. Three patients underwent surgery, chemotherapy, and radiotherapy, whereas one patient was treated with chemotherapy and radiotherapy. One patient with squamous cell carcinoma had other metastases in addition to GM and received chemotherapy and radiotherapy for the primary tumor.

Regarding bone cancers (n=3) one of the patients was 14 years old and stood out as the youngest patient in this group. Concerning the GM therapy, one of the patients with a known treatment underwent surgery and chemotherapy the other received only surgery. In all patients, GM was discovered metachronous. Three studies were included for soft tissue cancer. All three patients had metastases in addition to GM and underwent different types of GM treatment (including radiotherapy, chemotherapy, excision with snare, and cautery). For the thyroid cancer group, the median age was 71 years old. Overall survival (OS) was only mentioned for one patient (2.5 months). Regarding diffuse large B-cell lymphoma (DLBCL) (n=2), patients received chemotherapy for primary cancer and for GM. GM was discovered synchronously. Kovecsi et al., described the only case of GM from adrenocortical carcinoma of the adrenal gland.152 The patient underwent adrenalectomy for primary and total gastrectomy with splenectomy and end-to-side Roux-en-Y esophagojejunal anastomosis for GM. One patient with choriocarcinoma from retroperitoneum underwent chemotherapy for primary cancer and GM. Table 6 summarizes the findings of included studies regarding gastrointestinal cancers.151171

Table 6. Illustrating data regarding metastasis from other cancers.

First authorNo of casesAgeSexSite of primary tumorHistology type of primaryTreatment of primaryTreatment of MetastasisClinical presentation of GM
Kovecsi et al.152171MAdrenal glandAdrenocortical carcinomaRight adrenalectomyTotal gastrectomy, splenectomy, with end-to-side Roux-en-Y eso-jejunal anastomosisWeight loss, epigastric pain, vomiting, fatigue
Koti et al.153114FBoneEwing sarcomaChT, local excisionChT, total gastrectomy, RTAbdominal mass, low-grade fever, weight loss
Dodis et al.154172FBoneEwing sarcomaTotal knee replacements, RT, ChTN/AAnemia
Urakawa et al.155173MBoneOsteosarcomaChT, surgeryPartial gastrectomyAnemia, hematemesis
Shibuya et al.156127MExtragonadal retroperitonealChoriocarcinomaChtChTAbdominal pain, melena, vomiting
Tarangelo et al.157165MHead, neckSCCCht, RT, robotic excisionN/AMelenic bowel movements
Kamihara et al.158170MLymph nodesDLBCR-CHOP ChTR-CHOP ChTN/A
Zepeda-Gomez et al.159139FLymph nodesDLBCChT, omeprazoleChTMelena, weight loss, retroperitoneal mass
Teh et al.160137FOropharynxSCCSurgery, adjuvant RTPalliative RTWeight loss, LUQ pain, melena
Elkafrawy et al.161167MSkinMCCSurgery, consolidativeAtezolizumab, RTMelena
Ha et al.162182MSkinMCCSurgery, RTNoAnorexia, weight loss
Idowu et al.163179FSkinMCCSurgery, ChT, RTN/AAnemia
Parikh et al.164160MSkinMCCChT, RTChTMaroon colored stools
Subramanian et al.165162MSoft tissueLeiomyosarcomaSurgery, RTRT, ChTMelena, abdominal pain, nausea, vomiting
Dent et al.166160MSoft tissueSarcomaSurgeryRemove with snare and cauteryUpper abdominal pain, melena
Samuel et al.167156MSoft tissueSynovial sarcomaSurgery, RTDoxorubicinN/A
Thorburn et al.168156MSupraglottic larynx, hypopharynxAdvanced SCCSurgery, tracheostomy, radical RTN/AAnemia, hematemesis
Fuladi et al.169171FThyroidAnaplastic carcinomaTotal thyroidectomy, left modified radical neck dissection, RTN/ANausea, vomiting
Ayaz et al.170172MThyroidAnaplastic carcinomaN/AN/AMelena
Karrasch et al.171153FThyroidMedullary thyroid cancerComplete thyroidectomy ChTN/AFatigue, anorexia, epigastric pain radiating to the back

Discussion

Gastric metastases are uncommon and give information about the progressed stage of malignant disease, with a reported incidence of 0.2-0.7% based on clinical and autopsy findings.1 Furthermore, metastasis to the stomach frequently indicates short survival. These metastases are observed rarely due to clinical problems regarding their diagnosis and treatment.2 Progressively, with improvements in prognosis for cancer patients, metastatic tumors in the stomach are being detected more frequently.1 There are several symptoms of gastric metastases, such as abdominal pain, diarrhea, nausea, vomiting, weight loss, and dyspepsia. The most preferred treatment method for gastric metastasis is surgical resection of the tumor. Also, chemotherapy is the most applied alternative option.

This systematic review has a few potential limitations that need to be mentioned. As 172 case reports were screened in the systematic review from different journals the heterogeneity was inevitable. Some articles missed important information such as complete follow-up or clinical information. Moreover, since all of the included articles were case reports, quality or bias assessment could not be performed.

Gynecologic cancer

Gastric metastasis mainly occurs due to breast cancer. Both ovarian and uterine metastases are distinctly less frequent.38 Invasive lobular carcinoma is the type with the highest affinity to the digestive system with an incidence of 4.5% compared to 0.2% in ductal carcinoma.26 Breast cancer metastases to the gastrointestinal tract are rare, with a median time interval from the diagnosis of the primary tumor to metastasis up to seven years.21 The longest disease-free interval is 22 years after the initial diagnosis 17 of 24.10 Some metastatic tumors may have a similar presentation as primary gastric cancer.38 The detailed immunohistochemical analysis will allow the most accurate diagnosis to differentiate between primary gastric cancer and gastric metastasis from breast cancer.26 Most gastric metastatic breast cancers are estrogen receptor (ER)-positive, progesterone receptor (PR)-positive/negative, and human epidermal growth factor receptor (HER2)-negative. However, in primary gastric adenocarcinoma, ER and PR can be positively expressed in 20-28% of patients.19 In a few cases, metastatic breast cancer is negative for ER and PR, so a diagnosis cannot be made based on these two investigations alone.59 ER and PR can be used as markers; however, they are not always suitable diagnostic markers to confirm if a tumor has originated.11 Treatment of gastrointestinal metastases from breast cancer is discussed frequently in the literature. Systemic therapy is the first option.36 The effective rate of systemic treatment is about 46%.60 Surgical treatment may have a role in palliative treatment.34 Surgical treatment is considered in cases with obstruction or bleeding.36 Metastasis to the gastrointestinal tract can be the first presentation of breast cancer, therefore it is imperative to consider the possibility of breast cancer metastasis to the gastrointestinal metastasis.26,46

Gastrointestinal cancer

Among cancers that metastasize to the stomach, gastrointestinal system cancers are encountered in a minority. Gastric metastases gave unspecific findings, such as anemia, bleeding, and pain. Pancreas, liver, and colon account for the majority of primary cancers. Nine of the cases had other metastases in addition to gastric ones. Since pancreatic cancers are usually caught at an advanced stage, the chances of surgical treatment and their response to treatment are low. We see that three of five patients died within a year.2,6,8 Among these cases, the prognosis of pancreatic head cancers was worse than body and tail cancers.

Lung cancer

In fact, lung cancer is the most mortal type of all cancers. However, the stomach is not a common site for primary lung cancers’ metastases, especially compared with brain, liver, adrenal glands, and bones.74 Yet, the expected lifespan after diagnosis of metastasis is found to be relatively low. The median survival time was four months (average 6.8 months) among 16 cases who died. On the other hand, data showed that endoscopy is the gold standard in diagnosis. In addition, pathology and immunohistochemistry are considered important factors to differentiate gastric metastases from primary cancers.81 Regarding the treatment of gastric metastases of the pulmonary origin, although non-invasive chemotherapy treatments were the most common choice, patients who received surgery, particularly partial gastrectomy, but also esophagogastrostomy and laparotomy, tended to have relatively much longer survival time.77,90,95 However, this conclusion is not definitive, since in some cases surgeries may be avoided when the patient’s condition is extremely severe and the number of cases with given surgical treatments is scarce. So the potential benefit of surgeries to the expected lifespan of the patients needs further investigation.

Malign melanoma

Although melanoma accounts for only 5% of cutaneous malignancies, it makes up nearly 75% of skin cancer- related deaths.103,107 Malignant melanoma ranks as the most common metastatic tumor of the gastrointestinal (GI) tract.103,110,120 It takes an average of 52 months for a primary cutaneous melanoma to spread to the gastrointestinal tract.107,110 Only 1-4% of patients with malignant melanoma deceased before gastrointestinal metastases are diagnosed. On the other hand, GI tract metastasis was observed in more than 60% of melanoma patients by autopsy.103,110,111,114,121 The most commonly involved sites include the small and large bowels and rectum; however, gastric metastasis is a rare case110,111,117,119,121 due to the non-specificity of its symptoms, such as epigastric discomfort, nausea, vomiting, weight loss, hematemesis, and melena.103,107,110,111,114,117,121 The average survival is four to six months.103,107,121 Endoscopy is an effective method for detecting melanoma metastases due to pigmentation, which can then be confirmed by histology and immunohistochemistry.114,121 Treatment options include surgical resection, immunotherapy, chemotherapy, and targeted therapy. If a patient is symptomatic, surgical excision can be a palliative technique that can also prolong survival.103,121

Urogenital cancer

Regarding urogenital metastases GM is uncommon and the incidence is reported to vary between 0.2% and 0.7%.123 The most common clinical presentations are gastrointestinal bleeding (melena and hematemesis), anemia, and malaise. Whereas two patients had no symptoms associated with the gastrointestinal system.131,140 Esophagogastroduodenoscopy is often necessary for diagnosis and localized treatment.131 The presence of gastric metastases is considered an important indicator of advanced disease.149 Treatment options varied depending on the stage of the metastasis including endoscopic resection, partial or total gastrectomy, chemotherapy, and palliative care. Even though overall survival seems to be longer in patients who underwent surgery, the main reason for this may be that these patients have early-stage diseases suitable for surgery. Therefore, treatment options should be decided upon the stage of the disease and the general well-being of the patient.

Others

The most common symptoms, in terms of frequency, are melena, abdominal pain, vomiting, weight loss, anemia, fatigue, and loss of appetite. Gastrointestinal endoscopy plays an important role in the diagnosis of GM if suspected.162 Tumor seeding after endoscopic gastrostomy tube replacement was observed in two cases.161,169 Even though surgery is the frequent treatment for solid organ cancer metastasis, chemotherapy is the chosen treatment for DLBCL, skin cancer, and sarcoma. Overall survival was only mentioned for four cases; therefore, it is difficult to comment on which treatment method is more beneficial. Metastasis to the stomach is not reported frequently. Thus, determining the prognosis and planning the treatment based on scientific evidence seems to be problematic for clinicians.

In conclusion, among 172 case reports reviewed, resection surgery was performed the most for treatment and was sometimes combined with chemotherapy and immunotherapy. However, the literature regarding the management of patients with secondary gastric cancer is limited. Therefore, further multi-centric research to reach a consensus about what type of treatment has the best outcomes for patients with gastric metastases is needed.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 Oct 2023
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Ibrahimli A, Aliyev A, Majidli A et al. Metastasis to the stomach: a systematic review [version 1; peer review: 2 approved]. F1000Research 2023, 12:1374 (https://doi.org/10.12688/f1000research.140758.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 18 Oct 2023
Views
5
Cite
Reviewer Report 02 May 2024
Fabio Grizzi, Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Italy;  Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy 
Approved
VIEWS 5
I found Ibrahimii et al.'s manuscript on systematically reviewing stomach metastasis quite compelling. Their study stands out for its clarity and significance within its research domain. While I have some minor suggestions for the authors, such as delving deeper into ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Grizzi F. Reviewer Report For: Metastasis to the stomach: a systematic review [version 1; peer review: 2 approved]. F1000Research 2023, 12:1374 (https://doi.org/10.5256/f1000research.154145.r261964)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
9
Cite
Reviewer Report 02 Jan 2024
Murat Sarı, Marmara University, Istanbul, Turkey 
Approved
VIEWS 9
The stomach is a rare organ in terms of metastasis sites. It would be valuable to write a review evaluating this issue. The review is clearly the result of extensive research. Figures and tables are adequate and informative. Therefore, acceptance ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Sarı M. Reviewer Report For: Metastasis to the stomach: a systematic review [version 1; peer review: 2 approved]. F1000Research 2023, 12:1374 (https://doi.org/10.5256/f1000research.154145.r232517)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 Oct 2023
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.